Marginal Zone Lymphoma

hematologic malignancy

Identifier: CI-CAN-00008022
Entity page: /cancer/marginal-zone-lymphoma ↗
Edges: 509

Neighbours: 16 drugs10 trials
Drawn: 26 of 26 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Marginal Zone Lymphoma approved for …APPROVED_FOR4 of 4
← approved for	Zanubrutinibsmall_molecule 2 source records aggregated	supports	FDA ORIG	Marginal Zone Lymphoma	2	Regulatory	openfda	graph →
← approved for	Lenalidomidesmall_molecule	supports	FDA ORIG

Marginal Zone Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 98show all (up to 200)
→ investigated in trials for	Rituximabmonoclonal antibody 85 trials (28 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	85	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 43 trials (8 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 41 trials (10 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	41	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall_molecule 31 trials (13 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	31	Observed	clinicaltrials	graph →
→ investigated in trials for	Bendamustinesmall molecule 17 trials (5 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Obinutuzumabmonoclonal antibody 17 trials (8 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	17	Observed	clinicaltrials	graph →
→ investigated in trials for	Bortezomibsmall molecule 16 trials (0 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Zanubrutinibsmall_molecule 15 trials (9 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Ibrutinibsmall molecule 13 trials (6 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 12 trials (2 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Venetoclaxsmall molecule 11 trials (4 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 9 trials (1 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Busulfansmall molecule 8 trials (0 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 8 trials (1 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 8 trials (0 active) · roll-up of the cancer and its descendants	—	—	Marginal Zone Lymphoma	8	Observed	clinicaltrials	graph →

Marginal Zone Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 98show all (up to 200)

→ investigated in trials for

Rituximabmonoclonal antibody

85 trials (28 active) · roll-up of the cancer and its descendants

—

Marginal Zone Lymphoma

Observed

Marginal Zone Lymphoma studied in …STUDIED_INderived10 of 407show all (up to 200)
→ studied in	NCT05006716Phase 1/Phase 2 · recruiting A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05100862Phase 3 · active not recruiting A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06350318Phase 2 · recruiting Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06454149recruiting Cohort Study for Gastric MALT Lymphoma · condition mapped ALIAS · 407 trials mapped (134 active)	—	—	Gastric Mucosa-Associated Lymphoid Tissue Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05783596Phase 2 · active not recruiting Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06563596Phase 2 · recruiting Epco, Zanu, Ritux for R/R FL or MZL · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped CURATED_BROADER · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07101328Phase 1 · recruiting A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) · condition mapped ALIAS · 407 trials mapped (134 active)	—	—	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	1	Observed	clinicaltrials	graph →
→ studied in	NCT05296070Phase 2 · recruiting Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 407 trials mapped (134 active)	—	—	Marginal Zone Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains